Answers are grounded in this paper and cite their sources.
Identifies metabolic biomarkers for diagnosis and therapeutic monitoring in pediatric LCH, suggesting their potential use in clinical practice.
Alterations in BMA metabolic profiles within the LCH population and in specific metabolites may provide valuable insights into LCH pathogenesis and serve as biomarkers for diagnosis, prognosis, and therapeutic response assessment.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: